Company / Total Assets
Sarepta Therapeutics Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$3.3B
FY2025
5-year range
$3.1B / $4.0B
FY2021-FY2025
Trend
-15.5%
vs FY2024
Sector context
#31 of 214
Health Care
What the data says
Sarepta Therapeutics's total assets of $3.3B is higher than 86% of companies in the Health Care sector (FY2025). Total Assets has fluctuated over the past 10 years, ranging from $424M in FY2016 to $4.0B in FY2024.
Based on SEC 10-K filings.
$3.3B in FY2025 with a 5-year CAGR of +2.3%. Top quartile in the Health Care sector.
Improved from $3.3B to $3.3B over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +2.3%
- 5-Year CAGR
- +2.3%
- 10-Year CAGR
- -
Sector benchmark
Top 14% in Health CareTop 14% of 214This company $3.3B Sector average $7.5B
▼
-55.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +2.3%, indicating consistent growth.
- In FY2025, total assets decreased 15.5% year-over-year.
- Ranks #31 out of 214 companies in the Health Care sector.
- Peak total assets was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.3B | -15.5% |
| FY2024 | $4.0B | +21.4% |
| FY2023 | $3.3B | +4.4% |
| FY2022 | $3.1B | -0.6% |
| FY2021 | $3.1B | +5.5% |
| FY2020 | $3.0B | +63.7% |
| FY2019 | $1.8B | +11.0% |
| FY2018 | $1.6B | +25.5% |
| FY2017 | $1.3B | +208.4% |
| FY2016 | $424.1M | +54.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026